067630 — HLB Life Science Share Price
Last trade - 00:00- KR₩433bn
- KR₩582bn
- KR₩46bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.53 | ||
| Price to Tang. Book | 1.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.95 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.47% | ||
| Return on Equity | -11.11% | ||
| Operating Margin | -47.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 53,494.25 | 99,591.38 | 97,990.44 | 102,240.06 | 45,752.22 | n/a | n/a | -13% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -6.91 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
Directors
- Yang Gon Jin CEO (53)
- Sang Hwan Kim VCH (63)
- Seok Gon Choi VMG (60)
- Seong Nam Choi VPR (64)
- Sang Min Lee MDR (43)
- Hak Jeon Kim MDR (45)
- Mo Seok Lee OTH (47)
- Seong Ho Yim OTH (42)
- Chang Hyeon Kim DRC
- Seong Hyeon Lee DRC (48)
- Hyeong Heum Shim DRC (51)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 24th, 1998
- Public Since
- November 25th, 2008
- No. of Shareholders
- 73,703
- No. of Employees
- 187
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 121,847,138
- Address
- A-602, JnK Digital Tower, HWASEONG, 18469
- Web
- http://www.hlb-ls.com/
- Phone
- +82 226276700
- Auditors
- KPMG Samjong Accounting Corp
Latest News for 067630
Upcoming Events for 067630
Q3 2026 HLB Life Science Co Ltd Earnings Release
Q4 2026 HLB Life Science Co Ltd Earnings Release
HLB Life Science Co Ltd Annual Shareholders Meeting
Similar to 067630
AbClon
Korea Exchange - KOSDAQ
ADBiotech
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
AMINOLOGICS
Korea Exchange - KOSDAQ
FAQ
As of Today at 03:10 UTC, shares in HLB Life Science are trading at KR₩3,550. This share price information is delayed by 15 minutes.
Shares in HLB Life Science last closed at KR₩3,550 and the price had moved by -9.17% over the past 365 days. In terms of relative price strength the HLB Life Science share price has underperformed the FTSE Developed Asia Pacific Index by -32.55% over the past year.
There is no consensus recommendation for this security.
Find out moreHLB Life Science does not currently pay a dividend.
HLB Life Science does not currently pay a dividend.
HLB Life Science does not currently pay a dividend.
To buy shares in HLB Life Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩3,550, shares in HLB Life Science had a market capitalisation of KR₩433bn.
Here are the trading details for HLB Life Science:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 067630
Based on an overall assessment of its quality, value and momentum HLB Life Science is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HLB Life Science. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -17.95%.
As of the last closing price of KR₩3,550, shares in HLB Life Science were trading +1.58% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HLB Life Science PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩3,550.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
HLB Life Science's management team is headed by:
- Yang Gon Jin - CEO
- Sang Hwan Kim - VCH
- Seok Gon Choi - VMG
- Seong Nam Choi - VPR
- Sang Min Lee - MDR
- Hak Jeon Kim - MDR
- Mo Seok Lee - OTH
- Seong Ho Yim - OTH
- Chang Hyeon Kim - DRC
- Seong Hyeon Lee - DRC
- Hyeong Heum Shim - DRC